NARA Discovery
Article Details
← Back to Search Results
Journal Article

Engineered Extracellular Vesicles Loaded with MiR-100-5p Antagonist Selectively Target the Lesioned Region to Promote Recovery from Brain Damage

Yahong Cheng; Chengcheng Gai; Yijing Zhao; Tingting Li; Yan Song; Qian Luo; Danqing Xin; Zige Jiang; Wenqiang Chen; Dexiang Liu; Zhen Wang
Neuroscience Bulletin · Vol. 41, Issue 6 · pp. 1021-1040 · 2025

Abstract

Hypoxic-ischemic (HI) brain damage poses a high risk of death or lifelong disability, yet effective treatments remain elusive. Here, we demonstrated that miR-100-5p levels in the lesioned cortex increased after HI insult in neonatal mice. Knockdown of miR-100-5p expression in the brain attenuated brain injury and promoted functional recovery, through inhibiting the cleaved-caspase-3 level, microglia activation, and the release of proinflammation cytokines following HI injury. Engineered extracellular vesicles (EVs) containing neuron-targeting rabies virus glycoprotein (RVG) and miR-100-5p antagonists (RVG-EVs-Antagomir) selectively targeted brain lesions and reduced miR-100-5p levels after intranasal delivery. Both pre- and post-HI administration showed therapeutic benefits. Mechanistically, we identified protein phosphatase 3 catalytic subunit alpha (Ppp3ca) as a novel candidate target gene of miR-100-5p, inhibiting c-Fos expression and neuronal apoptosis following HI insult. In conclusion, our non-invasive method using engineered EVs to deliver miR-100-5p antagomirs to the brain significantly improves functional recovery after HI injury by targeting Ppp3ca to suppress neuronal apoptosis.

Bibliographic Information

JournalNeuroscience Bulletin
PublisherSpringer
Publication Date2025-06-01
Publication Year2025
Volume41
Issue6
Pages1021-1040
Document TypeJournal Article
Print ISSN1673-7067
eISSN1995-8218
DOI10.1007/s12264-025-01376-6

Access Information

NARA Access Coverage2007-01-01~Current
Journal Homepagehttps://www.springer.com/journal/12264
Publisher PageOpen Publisher Page
Full-text access depends on NARA's subscribed coverage and institutional access.